Galaxy Appoints Taeyong Park as New CEO...Shifts to Co-CEO Structure
Seok Chaok and Taeyong Park to Lead as Co-CEOs
Organizational Restructuring Ahead of 2027 IPO
Establishment of C-Level Executive Management System
Galaxy, an artificial intelligence (AI) drug development company, announced on the 28th that Taeyong Park, Executive Vice President, has been appointed as the new CEO, and that the company will shift to a co-CEO system with current CEO Seok Chaok. This organizational restructuring aims to strengthen the foundation for long-term growth and prepare for an initial public offering (IPO) targeted for the end of 2027.
From the left, Galaxy CEO Seok Chaok and newly appointed CEO Tae-yong Park. Galaxy
View original imageThe new CEO, Park, holds a bachelor's degree in Chemistry from KAIST and a doctorate from the Department of Chemistry at Seoul National University. Together with CEO Seok, he co-founded the company and has been responsible for investments, management, and business development. Under the co-CEO system, CEO Seok will oversee long-term vision and technology strategy, while CEO Park will take charge of research and development (R&D), commercialization, and overall company operations.
Galaxy has also established a C-level management structure for technology, AI, and finance. Co-founder Jonghun Won has assumed the role of Chief Technology Officer (CTO), and Executive Vice President Jin Sol Yang serves as Chief AI Officer (CAIO). In May, the company recruited Sunghyun Kim as Chief Financial Officer (CFO) to strengthen the firm's financial strategy and capital market response capabilities.
CEO Seok stated, "We have adopted the co-CEO structure to clarify roles and responsibilities and speed up decision-making at a time when the advancement of our AI platform, new drug development, global business expansion, and IPO preparations are all happening simultaneously." CEO Park commented, "Based on our proprietary AI technology and drug discovery capabilities, we aim to deliver breakthrough therapeutics and grow into a global leader in the biopharmaceutical industry."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Galaxy is a company that develops antibody and protein therapeutics utilizing its AI protein design platform, GaluxDesign.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.